Libtayo Adjuvant Treatment Shows Sustained Overall Survival Benefit in High-Risk Cutaneous Squamous Cell Carcinoma

Longer-term data, reflecting nearly four years of follow-up from the Phase 3 C-POST trial, demonstrate an increasing and clinically meaningful overall survival benefit with Libtayo® (cemiplimab) as adjuvant treatment for adults with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation. The data showed a 37% reduction in the risk of death at a median follow-up of 44 months. New prospective analyses also confirmed a sustained disease-free survival benefit, regardless of minimal residual disease status at baseline. These late-breaking results were presented at the European Society for Medical Oncology (ESMO) Congress 2026.